Genotropin is administered by subcutaneous injection (under the skin). It is available as a lyophilized powder in a cartridge or a pre-filled device (e.g., Genotropin Pen or Genotropin MiniQuick) that needs to be reconstituted before injection.
- Preparation: The powder is mixed with a diluent (liquid) contained within the device itself. Patients or caregivers receive thorough training on how to properly prepare and administer the injection.
- Administration:
- Injections are given subcutaneously, typically in areas like the thigh, buttocks, or abdomen.
- Injection sites should be rotated daily to prevent localized fat loss or skin irritation at the injection site (lipoatrophy).
- Dosage and Frequency:
- The dose is highly individualized, based on the patient’s condition, age, body weight, growth response (in children), and IGF-I levels.
- For pediatric patients, the weekly dose is typically divided into 6 or 7 subcutaneous injections given daily.
- For adults, dosing might be daily or several times a week.
- Dosage adjustments are made by a healthcare professional based on ongoing monitoring.
- Storage: Store Genotropin according to package instructions, often requiring refrigeration. Do not freeze.
Genotropin (somatropin) acts by binding to specific growth hormone (GH) receptors on target cells throughout the body, mimicking the actions of natural human growth hormone. Its effects are largely mediated through another hormone, Insulin-like Growth Factor-I (IGF-I), which is primarily produced in the liver in response to GH stimulation.
The key mechanisms of action include:
- Skeletal Growth: It stimulates the growth plates (epiphyses) in long bones, promoting linear growth in children before their growth plates close. It also affects bone metabolism, stimulating both bone formation (osteoblasts) and breakdown (osteoclasts) to promote bone mass accretion.
- Tissue Growth: It promotes overall tissue growth by increasing protein synthesis, cell proliferation, and cell differentiation. This leads to increased muscle mass and organ growth.
- Metabolism:
- Protein Metabolism: Increases nitrogen retention, leading to enhanced protein synthesis and muscle accretion.
- Carbohydrate Metabolism: Can increase blood glucose levels by influencing insulin sensitivity and glucose utilization.
- Lipid Metabolism: Stimulates the breakdown of fats (lipolysis), leading to a reduction in body fat stores, particularly abdominal visceral fat.
Mineral Metabolism: Influences the retention of potassium, phosphorus, and to a lesser extent, sodium, due to cell growth. It can increase serum phosphate levels and affect calcium balance.
Genotropin can cause various side effects, some of which can be significant and require medical attention.
- Common Side Effects:
- Injection Site Reactions: Pain, redness, swelling, inflammation, bleeding, bruising, lumps, or rash at the injection site.
- Fluid Retention (Edema): Swelling, particularly in hands, feet, and ankles (more common in adults, especially early in treatment).
- Joint Pain (Arthralgia) and Muscle Pain (Myalgia) / Stiffness: More common in adults.
- Headache.
- Nausea, vomiting.
- Fat loss (though overall body fat often decreases, localized fat loss at injection sites can occur if not rotated).
- Mildly increased blood sugar or changes in glucose metabolism.
- Low thyroid activity (hypothyroidism), which may require thyroid hormone replacement.
- Serious Side Effects (Seek immediate medical attention if these occur):
- Intracranial Hypertension (Pseudotumor Cerebri): Symptoms include severe headache, vision changes (e.g., blurred or double vision, decreased vision), nausea, vomiting. Requires prompt evaluation.
- Slipped Capital Femoral Epiphysis (SCFE): A hip problem in growing children, especially those with rapid growth, causing hip/knee pain or limping.
- Scoliosis Progression: Existing scoliosis (curvature of the spine) may worsen, particularly in children with rapid growth.
- Pancreatitis: Severe abdominal pain that may spread to the back, with or without nausea/vomiting.
- Diabetes Mellitus: New-onset diabetes or worsening of pre-existing diabetes.
- Increased Risk of Malignancy: While not definitively proven to cause new cancers, growth hormone might promote the growth of pre-existing malignancies. Patients with a history of cancer require careful monitoring.
- Allergic Reactions: Rash, hives, difficulty breathing or swallowing, swelling of the face, lips, or tongue.
- Sudden Death in Prader-Willi Syndrome: Particularly in patients who are severely obese, have a history of upper airway obstruction, sleep apnea, or severe respiratory impairment. This is a specific contraindication.
Genotropin can interact with several other medications, which may require dose adjustments or careful monitoring.
- Glucocorticoids (Corticosteroids): These can inhibit the growth-promoting effects of somatropin. Careful dose adjustment of glucocorticoids is necessary in children receiving both. Individuals on glucocorticoid replacement therapy may need an increased dose when starting Genotropin, as growth hormone can inhibit an enzyme (11β-hydroxysteroid dehydrogenase type 1) that converts cortisone to active cortisol.
- Oral Estrogens: Individuals, particularly women, taking oral estrogen replacement therapy may require higher doses of Genotropin to achieve the desired therapeutic effect, as estrogen can affect growth hormone sensitivity.
- Insulin and/or Oral/Injectable Hypoglycemic Agents: Since somatropin can affect carbohydrate metabolism and potentially increase blood glucose levels, individuals with diabetes requiring medication may need adjustments to their insulin or antidiabetic drug dosages when starting Genotropin therapy.
- Cytochrome P450-Metabolized Drugs: Genotropin may alter the clearance of drugs metabolized by certain liver enzymes (CYP450), such as corticosteroids, sex steroids, anticonvulsants, and cyclosporine. Careful monitoring is advisable.
- Thyroid Hormones: Growth hormone therapy can sometimes unmask central (secondary) hypothyroidism. Thyroid function should be monitored, and thyroid hormone replacement therapy may be needed.
Genotropin dosage is highly complex and must be individualized under the supervision of a physician experienced in the diagnosis and management of growth disorders and growth hormone deficiency. It is rarely a fixed dose and often adjusted based on patient response and biochemical markers.
- Administration: Subcutaneous injection, 6 or 7 times per week.
- Dosage Calculation: Doses are typically based on milligrams per kilogram of body weight per week (mg/kg/week) or sometimes a fixed daily dose for adults.
- Pediatric GHD: Generally, 0.16 to 0.24 mg/kg/week.
- Prader-Willi Syndrome: Generally, 0.24 mg/kg/week.
- Turner Syndrome: Generally, 0.33 mg/kg/week.
- Small for Gestational Age: Up to 0.48 mg/kg/week.
- Idiopathic Short Stature: Up to 0.47 mg/kg/week.
- Adult GHD: Initial dose often no more than 0.04 mg/kg/week, gradually increased to a maximum of 0.08 mg/kg/week based on clinical response and IGF-I levels.
- Monitoring: Regular monitoring of growth rate, IGF-I levels, thyroid function, and blood glucose is essential to optimize dosage and detect side effects.
Genotropin (somatropin) is a prescription-only medication. It is a highly specialized drug that requires:
- Specialist Prescription: It must be prescribed and managed by an endocrinologist or a physician experienced in the diagnosis and treatment of growth disorders or adult growth hormone deficiency.
- Detailed Diagnosis: A thorough diagnostic workup, including specific stimulation tests for growth hormone deficiency and genetic testing for certain syndromes, is required before initiation of therapy.
- Patient Training: Patients or caregivers must receive comprehensive training on proper injection techniques and storage.
- Ongoing Monitoring: Regular follow-up appointments, blood tests, and clinical assessments are necessary to monitor efficacy, adjust dosage, and detect potential side effects.
- Not for Cosmetic Use: It is not approved for use in healthy individuals for anti-aging purposes or muscle building, and such off-label use is considered dangerous and illegal
